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Background:  The  association  of  atrial  ﬁbrillation  (AF)  with  sudden  death  and  the  difference  in prognostic
signiﬁcance  between  paroxysmal  and  non-paroxysmal  AF remains  unclear  in patients  with  hypertrophic
cardiomyopathy  (HCM).  Our  aim  was to  investigate  the  clinical  signiﬁcance  of AF,  and to  assess  the
prognostic  difference  between  paroxysmal  and  non-paroxysmal  AF  in  HCM  patients.
Methods:  The  study  included  430  HCM  patients.  Documentation  of  AF was  based on  electrocardiograms
obtained  either  after  the  acute  onset  of  symptoms  or fortuitously  during  routine  examination  of asymp-
tomatic  patients.
Results: AF  was  detected  in  120  patients  (27.9%).  In the  patients  with  AF, syncope  and  non-sustained
ventricular  tachycardia  were  more  frequent  and  the  left  atrial  dimension  was  larger.  Multivariate  analysis
showed  that AF was  an  independent  determinant  of the  outcome,  including  the  risk  of  HCM-related
death (adjusted  hazard  ratio  3.57,  p < 0.001)  and sudden  death (adjusted  hazard  ratio  2.61,  p  =  0.038).
When  patients  with  AF were  divided  into  subgroups  with paroxysmal  AF  (n = 75)  or non-paroxysmal  AF
(n  =  45),  only  paroxysmal  AF was  identiﬁed  as an  independent  determinant  of the  outcome,  including  the
risk  of  HCM-related  death  (adjusted  hazard  ratio  5.24,  p <  0.001)  and  sudden  death  (adjusted  hazard  ratio
4.67,  p  = 0.002).
Conclusions:  AF  is  a  common  supraventricular  arrhythmia  in HCM  and  has  an  adverse  inﬂuence on
the  prognosis.  In addition,  each  type  of AF  had  a different  clinical  impact,  with  paroxysmal  AF being
a  signiﬁcant  independent  determinant  of  an  adverse  outcome,  including  sudden  death.
3  Jap© 201
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Hypertrophic cardiomyopathy (HCM) is a unique cardiovascu-
ar disease with a diverse clinical course [1–7]. Atrial ﬁbrillation
AF) is an important arrhythmia that is associated with systemic
hromboembolism, heart failure, and death in patients with HCM
8–12]. Previous clinical cohort studies have shown that AF is asso-
iated with a substantial increase in the overall risk of HCM-related
eath, but not sudden death [8,13]. On the other hand, there have
een several reports of AF triggering life-threatening ventricular
rrhythmias [14–20]. It thus remains controversial whether AF is
ssociated with sudden death in patients with HCM. In addition,
ew studies have assessed the difference in clinical impact between
he subsets of AF (paroxysmal or non-paroxysmal).
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Therefore, in the present study, we investigated the clinical sig-
niﬁcance of AF in HCM patients who were diagnosed and followed
at our hospital, as well as the prognostic impact of paroxysmal AF
vs. non-paroxysmal AF.
Methods
Study patients
The study population included 430 patients with a clinical diag-
nosis of HCM who were enrolled consecutively from 1980 to 2003 at
Tokyo Women’s Medical University Hospital (Tokyo, Japan). Initial
evaluation was deﬁned as the ﬁrst clinical assessment during which
an echocardiographic diagnosis of HCM was made. The most recent
evaluation was  ascertained on review at the clinic or by telephone
interview. Patients who had suffered from non-fatal cardiac arrest
or resuscitated cardiac arrest at the time of referral to our hospital
were excluded. This study was  carried out according to the princi-
ples of the Helsinki Declaration, and the protocol was approved by
the ethics committee of our hospital.
vier Ltd. All rights reserved.
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Among the 120 patients with AF, 22 (18%) died of causes related
to HCM during a mean follow-up period of 12.1 ± 7.3 years, includ-
ing 16 patients (13%) with sudden death, 4 (3.3%) who died of heart
Table 1
Clinical features of HCM  patients with or without AF.
Patients with AF Patients without AF p value
Number of patients, n
(%)
120 (27.9) 310 (72.1)
Age at diagnosis (years) 52.4 ± 13.0 49.7 ± 15.1 0.089
Male, n (%) 86 (71.7) 199 (64.2) 0.175
Duration of follow-up
(years)
12.1 ± 7.3 10.7 ± 7.3 0.083
Family history of
sudden death, n (%)
16 (13.3) 27 (8.7) 0.210
Syncope, n (%) 35 (29.2) 31 (10.0) <0.001
Non-sustained
ventricular
tachycardia, n (%)
70 (58.3) 102 (32.9) <0.001
Echocardiographic ﬁndings
Outﬂow tract
gradient ≥30 mm Hg,
n (%)
17 (14.2) 85 (27.4) 0.006
Maximum wall
thickness (mm)
19.9 ± 4.1 19.4 ± 4.1 0.264B. Yashiro et al. / Journal o
eﬁnitions
The diagnosis of HCM was based on echocardiographic identiﬁ-
ation of severe hypertrophy of the left ventricle in the absence of
nother systemic or cardiac disease that was capable of producing
imilar hypertrophy [10,11]. Left ventricular outﬂow tract obstruc-
ion was deﬁned as systolic obstruction (a gradient ≥30 mm Hg on
ontinuous-wave Doppler echocardiography) of the left ventricular
utﬂow tract at rest [10,11].
End-stage HCM was deﬁned by the detection of left ventricular
jection fraction <50% at rest, reﬂecting global systolic dysfunction,
n two-dimensional echocardiography without a history of surgical
r ablative septal reduction therapy during the follow-up period
4].
Documentation of AF was based on electrocardiograms obtained
ither after the acute onset of symptoms or fortuitously during
outine examination of patients without symptoms [8]. AF was
eﬁned as paroxysmal when it was self-terminating within 7 days,
r when sinus rhythm was successfully restored by electrical or
harmacologic cardioversion within 48 h [21]. AF was deﬁned as
on-paroxysmal when it progressed to persistent (sustained AF
eyond 7 days or successfully restored by electrical or pharma-
ologic cardioversion after 48 h of AF), longstanding-persistent
continuous AF of greater than 12 months’ duration), and perma-
ent (AF for which a decision has been made not to restore or
aintain sinus rhythm by any means) in this analysis [21]. Patients
hose AF evolved from paroxysmal to non-paroxysmal during
ollow-up were classiﬁed into the non-paroxysmal AF group.
In all patients, ambulatory electrocardiograms covering at least
4 h were reviewed for the detection of non-sustained ventricular
achycardia, which was deﬁned as a minimum of three consecutive
entricular beats at a rate ≥120/min [10,11].
For survival analysis, the following 3 modes of HCM-related
eath were deﬁned [22]: (1) sudden and unexpected death, which
eant collapse in the absence or <1 h after the onset of symptoms
n a patient who had previously been relatively stable (including
esuscitated cardiac arrest); (2) heart failure-related death, which
as deﬁned as occurring after progressive cardiac decompensation
or >1 year before death, particularly if complicated by pulmonary
dema or evolution to end-stage HCM; and (3) stroke-related death,
hich was deﬁned as death from ischemic stroke.
The following four clinical features were deﬁned as estab-
ished major primary prevention risk factors for sudden death
n the basis of previous reports [10,11]: (1) a family history of
udden death; (2) severe left ventricular hypertrophy (left ven-
ricular wall thickness in any myocardial segment ≥30 mm on
wo-dimensional echocardiography); (3) non-sustained ventricu-
ar tachycardia (three or more consecutive ventricular beats at a
ate ≥120/min); and (4) unexplained syncope. Abnormal exercise
lood pressure was excluded from the analysis because exercise
ests were not performed in all study HCM patients.
chocardiography
Echocardiographic studies were performed with commercially
vailable equipment. Complete two-dimensional, M-mode, and
oppler studies were done in the left lateral decubitus position
r the supine position, using the standard parasternal, apical, and
ubcostal views. The M-mode left atrial end-systolic dimension
as measured in the parasternal long-axis view. The severity and
istribution of left ventricular hypertrophy were assessed in the
hort-axis view by dividing the left ventricular wall into four seg-
ents (anterior septum, posterior septum, anterolateral wall, and
osterior wall) at the level of the mitral valve and also at the pap-
llary muscles. Maximal left ventricular wall thickness was  deﬁned
s the greatest thickness in any single segment. Left ventriculariology 63 (2014) 432–437 433
outﬂow tract obstruction was  quantiﬁed by continuous-wave
Doppler echocardiography under resting conditions.
Statistical analysis
Analyses were performed with SAS system ver. 9.1 software (SAS
Institute, Cary, NC, USA). Data are expressed as the mean ± standard
deviation or as frequencies. Student’s t-test was used to com-
pare continuous variables, while the chi-squared test or Fisher’s
exact test (when the expected value was <5) were used to com-
pare discrete variables between patients with or without AF and
patients with paroxysmal AF or non-paroxysmal AF. The proba-
bility of HCM-related death and sudden death was  estimated by
the Kaplan–Meier method, after which the log-rank test was used
to compare survival curves. Cox proportional-hazards regression
analysis was used to calculate hazard ratios and 95% conﬁdence
intervals for the relation between AF and survival. A p-value <0.05
was considered statistically signiﬁcant in all analyses.
Results
Baseline characteristics of the HCM patients with and without AF
Among the 430 patients enrolled with HCM, AF was documented
in 120 patients and its prevalence was 27.9%. The baseline charac-
teristics of the patients with and without AF are shown in Table 1.
Onset of AF was  detected at ages from 21 to 84 years (average:
56 ± 13 years). There were no signiﬁcant differences with respect
to gender, family history of sudden death, or maximum left ven-
tricular wall thickness between the patients with and without AF.
The patients with AF were older than those without AF, but the
difference was not signiﬁcant. In the AF group, syncope was more
frequent, non-sustained ventricular tachycardia was documented
more often, and the left atrial dimension was larger than in the
group without AF. In contrast, left ventricular outﬂow tract obstruc-
tion was signiﬁcantly more frequent among patients without AF.
Outcome in patients with or without AFLeft atrial dimension
(mm)
41.8  ± 8.7 35.1 ± 6.4 <0.001
Values with ± represent the mean ± SD. AF, atrial ﬁbrillation; HCM,  hypertrophic
cardiomyopathy.
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ailure, and 2 (1.7%) who died of HCM-related ischemic stroke. Pro-
ression to end-stage HCM was more likely in the AF group than
n those without AF [n = 25 (20.8%) vs. n = 24 (7.7%), p < 0.001]. In
ddition, nonfatal ischemic stroke was signiﬁcantly more frequent
n the AF group than in patients without AF [n = 32 (26.7%) vs. n = 16
5.2%), p < 0.001]. According to univariate analysis, the AF group had
 signiﬁcantly greater risk of HCM-related death than the patients
ithout AF (p < 0.001, Fig. 1A). The probability of sudden death
mong patients from the AF group was also signiﬁcantly higher
han among patients without AF (p < 0.001, Fig. 1B). When multi-
ariate analysis was done with AF, enlarged left atrium ≥46 mm
23], left ventricular outﬂow tract obstruction [24], and the four
ajor risk factors for sudden death (family history of sudden death,
aximum left ventricular wall thickness ≥30 mm,  non-sustained
entricular tachycardia, and unexplained syncope), it was found
hat AF was an independent determinant of the outcome, including
he risk of HCM-related death (adjusted hazard ratio 3.57, 95% con-
dence interval 1.70–7.49, p < 0.001) and the risk of sudden death
adjusted hazard ratio 2.61, 95% conﬁdence interval 1.06–6.47,
 = 0.038).
omparison between paroxysmal AF and non-paroxysmal AF
Among the 120 patients with AF, paroxysmal AF was docu-
ented in 75 patients (63%) and non-paroxysmal AF was  detected
n 45 patients (37%). Twenty-eight (23%) patients showed evo-
ution from paroxysmal AF to non-paroxysmal AF during the
ollow-up period. These patients whose AF evolved from parox-
smal to non-paroxysmal (n = 28) were similar to the patients
ith non-paroxysmal AF from the beginning (n = 17), and no
tatistically signiﬁcant differences were observed between the
wo groups in terms of age at diagnosis (54.6 ± 10.3 years vs.
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ig. 1. Outcome in HCM patients with or without AF. Cumulative probability
Kaplan–Meier estimate) of overall HCM-related death (A) and sudden death (B)
n  120 patients who  developed AF during the follow-up period compared to 310
atients without AF. AF, atrial ﬁbrillation; HCM, hypertrophic cardiomyopathy.iology 63 (2014) 432–437
51.2 ± 9.4 years, p = 0.283), maximum wall thickness
(20.2 ± 4.5 mm vs. 19.4 ± 3.4 mm,  p = 0.531), left atrial dimen-
sion (41.9 ± 9.3 mm vs. 47.1 ± 9.3 mm,  p = 0.078), gender (male
67.9% vs. 94.1%, p = 0.064), prevalence of syncope (25.0% vs.
17.6%, p = 0.719), non-sustained ventricular tachycardia (71.4% vs.
58.8%, p = 0.582), family history of sudden death (14.3% vs. 11.8%,
p > 0.999), and HCM-related death rate (14.3% vs. 11.8%, log-rank
p = 0.797). In addition, all HCM-related events occurred after the
evolution to non-paroxysmal AF in patients with AF evolved from
paroxysmal to non-paroxysmal. Therefore, we classiﬁed these
patients into the non-paroxysmal AF group (total n = 45) in the
following analysis. The baseline characteristics of the 75 patients
with paroxysmal AF and 45 patients with non-paroxysmal AF are
shown in Table 2. There was  no signiﬁcant difference in the age
at diagnosis of HCM, age at onset of AF, and gender between the
patients with paroxysmal or non-paroxysmal AF. In addition, there
was no signiﬁcant difference in the occurrence of syncope, the
severity of left ventricular hypertrophy, the prevalence of non-
sustained ventricular tachycardia, and the family history of sudden
death. In the patients with paroxysmal AF, left ventricular outﬂow
tract obstruction was  signiﬁcantly more frequent than in those
with non-paroxysmal AF. In contrast, the left atrial dimension was
larger in the patients with non-paroxysmal AF than in those with
paroxysmal AF.
Outcome of paroxysmal AF and non-paroxysmal AF
Sixteen out of 75 patients with paroxysmal AF (29%) suffered
from HCM-related death, including sudden death (n = 14, 19%) and
heart failure-related death (n = 2, 2.7%). Among the 45 patients with
non-paroxysmal AF, 6 (13%) died of causes related to HCM, includ-
ing 2 (4.4%) who died suddenly, 2 (4.4%) who died of heart failure,
and 2 (4.4%) who  died of HCM-related ischemic stroke (Fig. 2). There
was a signiﬁcant difference in the mean interval from the onset of
AF to HCM-related death between patients with paroxysmal AF and
those with non-paroxysmal AF (5.1 ± 4.2 years vs. 11.9 ± 8.3 years,
p = 0.020). According to univariate analysis, paroxysmal AF was
associated with a marked increase in the risk of both HCM-related
death (p < 0.001, Fig. 3A) and sudden death (p < 0.001, Fig. 3B). Non-
paroxysmal AF was a substantial risk factor for HCM-related death
Table 2
Clinical features of HCM patients with paroxysmal AF or non-paroxysmal AF.
Paroxysmal AF Non-paroxysmal AF p value
Number of patients, n
(%)
75 (62.5) 45 (37.5)
Age at diagnosis of
HCM (years)
51.8 ± 14.5 53.3 ± 10.0 0.535
Age  at onset of AF
(years)
56.5 ± 13.3 55.7 ± 12.5 0.744
Male, n (%) 51 (68.0) 35 (77.8) 0.346
Duration of follow-up
(years)
11.0 ± 7.7 13.8 ± 6.2 0.042
Family history of
sudden death, n (%)
10 (13.3) 6 (13.3) >0.999
Syncope, n (%) 25 (33.3) 10 (22.2) 0.276
Non-sustained
ventricular
tachycardia, n (%)
40 (53.3) 30 (66.7) 0.214
Echocardiographic ﬁndings
Outﬂow tract
gradient ≥30 mm Hg,
n (%)
16 (21.3) 1 (2.2) 0.008
Maximum wall
thickness (mm)
19.8 ± 4.1 19.9 ± 4.1 0.899
Left atrial dimension
(mm)
40.5 ± 7.9 43.9 ± 9.6 0.040
Values with ± represent the mean ± SD. AF, atrial ﬁbrillation; HCM, hypertrophic
cardiomyopathy.
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p = 0.029, Fig. 3A), but not for sudden death (p = 0.745, Fig. 3B).
hen multivariate analysis was done with entry of paroxysmal AF,
on-paroxysmal AF, left atrial enlargement (≥46 mm),  left ventri-
ular outﬂow tract obstruction, and the four established major risk
actors for sudden death, paroxysmal AF was identiﬁed as an inde-
endent determinant of the outcome, including the risk of HCM-
elated death (adjusted hazard ratio 5.24, 95% conﬁdence interval
.35–11.7, p < 0.001) and the risk of sudden death (adjusted hazard
atio 4.67, 95% conﬁdence interval 1.80–12.1, p = 0.002). In contrast,
on-paroxysmal AF was not identiﬁed as an independent risk factor
or HCM-related death (adjusted hazard ratio 2.36, 95% conﬁdence
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interval 0.843–6.63, p = 0.102) or sudden death (adjusted hazard
ratio 0.843, 95% conﬁdence interval 1.72–4.14, p = 0.834).
Discussion
In the present single-center HCM cohort, AF was documented in
28% of the patients. The patients with AF were more likely to have
prognostic risk factors, including syncope, non-sustained ventri-
cular tachycardia, and left atrial enlargement, when compared to
the patients without AF, but multivariate analysis revealed that AF
was still an independent determinant of both HCM-related death
and sudden death. Furthermore, investigation of the difference
between paroxysmal AF and non-paroxysmal AF demonstrated
that only paroxysmal AF was strongly associated with both HCM-
related death and sudden death.
AF is the most common supraventricular arrhythmia in HCM
patients. In our cohort of 430 patients with HCM, the preva-
lence of AF was 28%, which was  similar to that found in previous
cohort studies [3,8,10]. We  also divided the patients with AF,
according to expert consensus statement on AF, into paroxysmal
and non-paroxysmal AF groups [21]. We deﬁned non-paroxysmal
AF as relatively established arrhythmia (persistent, longstanding-
persistent, and permanent AF) or as AF that progressed from
paroxysmal to non-paroxysmal during follow-up. Although we
realize the limitations of this deﬁnition, it allowed comparison
between pure paroxysmal AF and other forms. In the present study,
63% of the patients with AF had paroxysmal AF, a higher percent-
age than in previous studies which showed a prevalence of less than
50% among HCM patients with AF [1,8,25]. A possible explanation
for the higher percentage of paroxysmal AF in the present patient
cohort is that our hospital is a tertiary referral center and even
subclinical paroxysmal AF without symptoms may be detected by
careful examinations (including 24-h ambulatory electrocardiogra-
phy) that are done several times a year. Another possible reason is
that patients with AF who are at risk of hemodynamic deterioration
may  be referred to our center for aggressive treatment to prevent
progression to non-paroxysmal AF, including amiodarone therapy
and electrical cardioversion within 48 h. Despite this being a highly
selected population of HCM patients from a single large tertiary
referral center in Japan, our study revealed some interesting epi-
demiologic information about paroxysmal and non-paroxysmal AF
in a relatively large cohort.
The present study identiﬁed AF as a substantial risk for overall
HCM-related death and our results also demonstrated an associ-
ation of AF with sudden death. A strong independent association
between AF and HCM-related mortality was previously demon-
strated by Olivotto and colleagues in a community-based HCM
population, and this ﬁnding is consistent with our results [8]. How-
ever, no association was detected between AF and sudden death in
a previous study [8], and AF is not listed as a risk factor for sudden
death in the current guideline for HCM [11]. On the other hand,
it has been suggested that in certain susceptible HCM patients,
AF may  trigger life-threatening ventricular arrhythmias [10,26].
Therefore, the relationship between AF and sudden death remains
controversial in patients with HCM, and this is an important area
for further research.
In the present study, we  investigated the difference between
the prognostic inﬂuence of paroxysmal AF and non-paroxysmal
AF. Few studies have separately analyzed the prognostic impact of
these two  subsets of AF on the clinical course of HCM, especially
sudden death. Therefore, current guidelines do not distinguish
between paroxysmal and non-paroxysmal AF [11]. In our present
HCM cohort, sudden death was the most common cause of death
among patients with paroxysmal AF who died of HCM-related
causes, and multivariate analysis identiﬁed paroxysmal AF as a
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igniﬁcant independent determinant of sudden death. Further-
ore, Olivotto et al. similarly reported that 7 out of 45 patients
15.6%) who exclusively had paroxysmal AF experienced sudden
nexpected death, while only 6 out of 62 patients (9.7%) with
hronic AF died suddenly [8]. On the other hand, no deﬁnite trend in
he mode of death was found for patients with non-paroxysmal AF
n the present study, as shown in Fig. 2. The disparity of the impact
f these two types of AF on sudden death suggests that paroxysmal
F may  play an important and decisive role in triggering lethal car-
iac events, and emphasizes the necessity for aggressive treatment
uring the paroxysmal phase of AF in HCM patients [27,28].
Several mechanisms by which ventricular arrhythmia could be
irectly induced by AF with a rapid ventricular response have
een proposed including silent myocardial ischemia [15,19,20],
nhanced atrioventricular node conduction [19], and short-long
hort ventricular cycle sequences followed by ventricular tachycar-
ia [14,15]. Patients with HCM are more susceptible to myocardial
schemia because of small vessel abnormalities, such as thick-
ned walls and limited luminal area [2,29,30], and this has been
egarded as one of the most essential pathophysiological features
hat promotes ischemic damage to the ventricular myocardium
29,31,32] and inﬂuences the outcome of HCM [33,34]. In the set-
ing of acute hemodynamic changes, tachycardia, or both, there is
n increase in the oxygen demand of the hypertrophied ventricu-
ar myocardium and elevation of intraventricular pressure, so the
entricular myocardium of HCM patients is exposed to additional
actors promoting ischemia. It is thus possible that paroxysmal
pisodes of AF are responsible for acute clinical deterioration as
 result of reduced diastolic ﬁlling and reduced cardiac output,
ith such adverse hemodynamic effects being due to an incre-
ent of the ventricular rate (caused by enhanced atrioventricular
onduction) and loss of atrial contraction following the onset of
F, particularly in patients who have left ventricular hypertrophy
ssociated with pre-existing diastolic dysfunction [8,19,20]. Con-
equently, the combination of a sudden rapid ventricular response
nd these abrupt hemodynamic changes during paroxysmal AF
ould cause myocardial ischemia [20,35], which may  augment
otential arrhythmogenic substrates and lead to life-threatening
entricular tachyarrhythmia. However, such a hypothesis cannot
pply to all HCM patients with paroxysmal AF who die suddenly,
o further studies are needed to clarify the relationship between
aroxysmal AF and sudden death in HCM.
The ventricular response during AF is inﬂuenced by various
actors, such as medications, autonomic tone, and the intrinsic
efractoriness of the atrioventricular node. Provided that atrioven-
ricular conduction is not blocked, the ventricular rate increases
hen the atrial rate is relatively slow during AF. Conversely, a
aster atrial rate is associated with a slower ventricular rate because
f concealed conduction in the atrioventricular node that alters
trioventricular nodal refractoriness to slow or block subsequent
trial impulses [36]. Shortening of the atrial ﬁbrillatory cycle length,
hich is inversely related to atrial ﬁbrillatory rate, and atrial
efractoriness are hallmarks of atrial electrical remodeling [37]. An
lectrophysiological study in dogs has demonstrated that the aver-
ge atrial ﬁbrillatory rate is signiﬁcantly shorter in patients with
hronic AF than in those with paroxysmal AF [38]. Moreover, func-
ional electrophysiological remodeling of the atrioventricular node
ccurs during long-term AF, which could lead to spontaneous slow-
ng of the ventricular rate [39]. These observations suggest that
 sudden rapid ventricular response will not easily occur in non-
aroxysmal AF, especially in patients receiving pharmacological
ate control therapy. Therefore, refractoriness to a sudden rapid
entricular response is one possible reason why non-paroxysmal
F showed no signiﬁcant association with an increased incidence
f sudden death in our HCM cohort. Interestingly, the mean inter-
al from the occurrence of AF to HCM-related death in our patientsiology 63 (2014) 432–437
with non-paroxysmal AF was signiﬁcantly longer than in those with
paroxysmal AF, representing the difference of prognostic impact
between these two types of AF.
Limitations
The present investigation was retrospective and was  done at a
single tertiary center, so it may  have had certain inherent selec-
tion biases. Further large-scale, multicenter, and/or multinational
studies are needed to extend the current ﬁndings. In addition, the
diagnosis of AF in this study was mainly based on electrocardio-
grams and 24-h ambulatory electrocardiograms, which are not fully
reliable for detecting paroxysmal AF, so it is therefore likely that
we underestimated the true prevalence of AF among patients with
HCM. Furthermore, we  should examine the prognostic effect of
drug use in study HCM patients, especially of antiarrhythmic drugs
because of their proarrhythmic effect. In this study, however, we
could not evaluate it in detail, because we cannot fully access the
data of drug treatment in all study HCM patients.
Conclusions
In our HCM patient cohort, AF was  a common supraventricular
arrhythmia and it had an adverse effect on the prognosis, includ-
ing sudden death. We  also demonstrated that each type of AF had
a different clinical impact, with paroxysmal AF being a signiﬁcant
independent determinant of an adverse outcome. It may  be neces-
sary to give careful consideration to the prevention of sudden death
in HCM patients during the paroxysmal phase of AF.
Author’s contribution
Bun Yashiro contributed to concept/design, data collection, data
analysis, drafting article, approval of article; Yuichiro Minami con-
tributed to concept/design, data collection, data interpretation,
statistics, drafting article, approval of article; Yutaka Terajima
contributed to concept/design, data analysis, critical revision of
article, approval of article; Nobuhisa Hagiwara contributed to con-
cept/design, data interpretation, critical revision of article, approval
of article.
Conﬂict of interest
There is no conﬂict of interest and ﬁnancial disclosure in our
manuscript for all the authors.
Acknowledgments
We  wish to express our gratitude to Katsuya Kajimoto, MD and
Koichiro Ejima, MD for their excellent clinical assistance and to Kat-
sunori Shimada, PhD (STATZ Institute, Inc., Tokyo, Japan) for his
expert statistical assistance.
References
[1] Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic
cardiomyopathy in Tuscany: clinical course and outcome in an unselected
regional population. J Am Coll Cardiol 1995;26:1529–36.
[2] Maron BJ. Hypertrophic cardiomyopathy: a systematic review.
JAMA 2002;287:1308–20.
[3] Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical
course of hypertrophic cardiomyopathy in a regional United States cohort.
JAMA 1999;281:650–5.
[4] Goto D, Kinugawa S, Hamaguchi S, Sakakibara M,  Tsuchihashi-Makaya M,
Yokota T, Yamada S, Yokoshiki H, Tsutsui H, for the JCARE-CARD Investigators.
Clinical characteristics and outcomes of dilated phase of hypertrophic car-
diomyopathy: report from the registry data in Japan. J Cardiol 2013;61:65–70.
f Card
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[B. Yashiro et al. / Journal o
[5] Kubo T, Kitaoka H, Okawa M,  Hirota T, Hayato K, Yamasaki N, Matsumura Y,
Yabe T, Doi YL. Gender-speciﬁc differences in the clinical features of hyper-
trophic cardiomyopathy in a community-based Japanese population: results
from Kochi RYOMA study. J Cardiol 2010;56:314–9.
[6] Kitaoka H, Kubo T, Baba Y, Yamasaki N, Matsumura Y, Furuno T, Doi YL. Serum
tenascin-C levels as a prognostic biomarker of heart failure events in patients
with hypertrophic cardiomyopathy. J Cardiol 2012;59:209–14.
[7] Jenab Y, Pourjafari M,  Darabi F, Boroumand MA,  Zorouﬁan A, Jalali A.
Prevalence and determinants of elevated high-sensitivity cardiac troponin T
in  hypertrophic cardiomyopathy. J Cardiol 2013 http://dx.doi.org/10.1016/j.
jjcc.2013.07.008
[8] Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial
ﬁbrillation on the clinical course of hypertrophic cardiomyopathy. Circulation
2001;104:2517–24.
[9] Olivotto I, Maron BJ, Cecchi F. Clinical signiﬁcance of atrial ﬁbrillation in hyper-
trophic cardiomyopathy. Curr Cardiol Rep 2001;3:141–6.
10] Maron BJ, McKenna WJ,  Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE,
Shah  PM, Spencer 3rd WH,  Spirito P, Ten Cate FJ, Wigle ED. American College
of  Cardiology/European Society of Cardiology Clinical Expert Consensus Doc-
ument on Hypertrophic Cardiomyopathy. A report of the American College of
Cardiology Foundation Task Force on Clinical Expert Consensus Documents
and the European Society of Cardiology Committee for Practice Guidelines. Eur
Heart J 2003;24:1965–91.
11] Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA,  Link MS,  Naidu SS,
Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE,
Yancy CW.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of
Hypertrophic Cardiomyopathy A Report of the American College of Cardiol-
ogy Foundation/American Heart Association Task Force on Practice Guidelines
Developed in Collaboration With the American Association for Thoracic
Surgery, American Society of Echocardiography, American Society of Nuclear
Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for
Cardiovascular Angiography and Interventions, and Society of Thoracic Sur-
geons. J Am Coll Cardiol 2011;58:e212–60.
12] Shigematsu Y, Hamada M,  Nagai T, Nishimura K, Inoue K, Suzuki J, Ogimoto A,
Higaki J. Risk for atrial ﬁbrillation in patients with hypertrophic cardiomyopa-
thy: association with insulin resistance. J Cardiol 2011;58:18–25.
13] Kofﬂard MJ,  Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic car-
diomyopathy in a large community-based population: clinical outcome and
identiﬁcation of risk factors for sudden cardiac death and clinical deterioration.
J  Am Coll Cardiol 2003;41:987–93.
14] Boriani G, Rapezzi C, Bifﬁ M,  Branzi A, Spirito P. Atrial ﬁbrillation precipitating
sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Cardio-
vasc Electrophysiol 2002;13:954.
15] Brembilla-Perrot B, Grentzinger A, Guenoun P, Giorgi JP, Licho T. Initiation of
ventricular ﬁbrillation by atrial ﬁbrillation. Eur Heart J 1994;15:289–91.
16] Elliott PM,  Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ.  Sur-
vival after cardiac arrest or sustained ventricular tachycardia in patients with
hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596–601.
17] Favale S, Pappone C, Nacci F, Fino F, Resta F, Dicandia CD. Sudden death due
to  atrial ﬁbrillation in hypertrophic cardiomyopathy: a predictable event in a
young patient. Pacing Clin Electrophysiol 2003;26:637–9.
18] Limongelli G, Elliott PM,  Pacileo G, Sarubbi B, Thaman R, Calabro P, Vergara
P,  Iacomino M,  Russo MG,  Calabro R. Noninvasive risk stratiﬁcation prevents
sudden death due to paroxysmal atrial ﬁbrillation in hypertrophic cardiomy-
opathy. J Cardiovasc Med  (Hagerstown) 2006;7:711–3.
19] Stafford WJ,  Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ.
Cardiac arrest in an adolescent with atrial ﬁbrillation and hypertrophic car-
diomyopathy. J Am Coll Cardiol 1986;7:701–4.
20] Suzuki M,  Hirayama T, Marumoto K, Okayama H, Iwata T. Paroxysmal atrial
ﬁbrillation as a cause of potentially lethal ventricular arrhythmia with myocar-
dial  ischemia in hypertrophic cardiomyopathy—a case report. Angiology
1998;49:653–7.
21] Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano
Jr  RJ, Davies DW,  DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD,  Haines
DE,  Haissaguerre M,  et al. 2012 HRS/EHRA/ECAS expert consensus statement
on  catheter and surgical ablation of atrial ﬁbrillation: recommendations for
patient selection, procedural techniques, patient management and follow-up,
deﬁnitions, endpoints, and research trial design: a report of the Heart Rhythm
Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrilla-
tion. Developed in partnership with the European Heart Rhythm Association
(EHRA), a registered branch of the European Society of Cardiology (ESC) and
the European Cardiac Arrhythmia Society (ECAS); and in collaboration with
the American College of Cardiology (ACC), American Heart Association (AHA),
the Asia Paciﬁc Heart Rhythm Society (APHRS), and the Society of Thoracic
Surgeons (STS). Endorsed by the governing bodies of the American College of
Cardiology Foundation, the American Heart Association, the European Cardiac
[
[iology 63 (2014) 432–437 437
Arrhythmia Society, the European Heart Rhythm Association, the Society of
Thoracic Surgeons, the Asia Paciﬁc Heart Rhythm Society, and the Heart Rhythm
Society. Heart Rhythm 2012;9:632–96, e21.
22] Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ,
Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related
death: revisited in a large non-referral-based patient population. Circulation
2000;102:858–64.
23] Nistri S, Olivotto I, Betocchi S, Losi MA,  Valsecchi G, Pinamonti B, Conte MR,
Casazza F, Galderisi M,  Maron BJ, Cecchi F. Prognostic signiﬁcance of left atrial
size in patients with hypertrophic cardiomyopathy (from the Italian Registry
for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98:960–5.
24] Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA,  Cecchi F, Maron
BJ.  Effect of left ventricular outﬂow tract obstruction on clinical outcome in
hypertrophic cardiomyopathy. N Engl J Med  2003;348:295–303.
25] Maron BJ, Olivotto I, Bellone P, Conte MR,  Cecchi F, Flygenring BP, Casey SA,
Gohman TE, Bongioanni S, Spirito P. Clinical proﬁle of stroke in 900 patients
with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–7.
26] Zipes DP, Camm AJ, Borggrefe M,  Buxton AE, Chaitman B, Fromer M,  Gregoratos
G,  Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA,  Roden DM,  Silka MJ,
Tracy C, et al. ACC/AHA/ESC 2006 guidelines for management of patients with
ventricular arrhythmias and the prevention of sudden cardiac death—executive
summary: a report of the American College of Cardiology/American Heart
Association Task Force and the European Society of Cardiology Committee for
Practice Guidelines (Writing Committee to Develop Guidelines for Manage-
ment of Patients with Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death) Developed in collaboration with the European Heart Rhythm
Association and the Heart Rhythm Society. Eur Heart J 2006;27:2099–140.
27] Bunch TJ, Munger TM,  Friedman PA, Asirvatham SJ, Brady PA, Cha YM,  Rea
RF,  Shen WK,  Powell BD, Ommen SR, Monahan KH, Haroldson JM,  Packer DL.
Substrate and procedural predictors of outcomes after catheter ablation for
atrial ﬁbrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc
Electrophysiol 2008;19:1009–14.
28] Maron BJ, Spirito P. Implantable deﬁbrillators and prevention of
sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol
2008;19:1118–26.
29] Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic
cardiomyopathy and sudden death in the young: pathologic evidence of
myocardial ischemia. Hum Pathol 2000;31:988–98.
30] Varnava AM,  Elliott PM,  Sharma S, McKenna WJ,  Davies MJ.  Hypertrophic car-
diomyopathy: the interrelation of disarray, ﬁbrosis, and small vessel disease.
Heart 2000;84:476–82.
31] Petersen SE, Jerosch-Herold M,  Hudsmith LE, Robson MD, Francis JM,  Doll
HA,  Selvanayagam JB, Neubauer S, Watkins H. Evidence for microvas-
cular dysfunction in hypertrophic cardiomyopathy: new insights from
multiparametric magnetic resonance imaging. Circulation 2007;115:
2418–25.
32] Sotgia B, Sciagra R, Olivotto I, Casolo G, Rega L, Betti I, Pupi A, Camici PG, Cecchi F.
Spatial relationship between coronary microvascular dysfunction and delayed
contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl
Med  2008;49:1090–6.
33] Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary
microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N
Engl J Med 2003;349:1027–35.
34] Maron MS,  Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, Camici PG.
The  case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll
Cardiol 2009;54:866–75.
35] Cannon 3rd RO, Schenke WH,  Maron BJ, Tracy CM,  Leon MB,  Brush Jr JE, Rosing
DR, Epstein SE. Differences in coronary ﬂow and myocardial metabolism at rest
and during pacing between patients with obstructive and patients with nonob-
structive hypertrophic cardiomyopathy. J Am Coll Cardiol 1987;10:53–62.
36] Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin
JL,  Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann
S.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial
ﬁbrillation-executive summary: a report of the American College of Cardiol-
ogy/American Heart Association Task Force on Practice Guidelines and the
European Society of Cardiology Committee for Practice Guidelines (Writing
Committee to Revise the 2001 Guidelines for the Management of Patients with
Atrial Fibrillation). Eur Heart J 2006;27:1979–2030.
37] Wijffels MC,  Kirchhof CJ, Dorland R, Allessie MA.  Atrial ﬁbrillation begets
atrial ﬁbrillation. A study in awake chronically instrumented goats. Circulation
1995;92:1954–68.38] Sih HJ, Zipes DP, Berbari EJ, Adams DE, Olgin JE. Differences in organiza-
tion between acute and chronic atrial ﬁbrillation in dogs. J Am Coll Cardiol
2000;36:924–31.
39] Zhang Y, Mazgalev TN. Atrioventricular node functional remodeling induced
by  atrial ﬁbrillation. Heart Rhythm 2012;9:1419–25.
